GSK Announces Positive Topline Data on Co-Administration of AREXVY …
WEB5 days ago · PHILADELPHIA, September 18, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity ...
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older. Late-stage RSV vaccine trials show 'exciting...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
GSK Announces Positive Topline Data on Co-Administration of AREXVY …
WEB5 days ago · PHILADELPHIA-- (BUSINESS WIRE)-- #Adult --GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant ...
US FDA approves expanded age indication for GSK’s AREXVY, the …
WEBJun 7, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk.
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the …
WEBJun 7, 2024 · AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: Individuals 60 years of age and...
FDA approves first RSV vaccine, Arexvy, for adults 60 and ... - ABC7 News
WEBMay 3, 2023 · The FDA approved the first RSV vaccine Wednesday, called Arexvy, which is designed to be given as a single shot to adults 60 and over. After a 60-year scientific quest, the world has its first...
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
WEBJun 10, 2024 · Arexvy was the first RSV vaccine for older adults to be approved anywhere in the world. Arexvy had an exceptional launch and generated £1.2 billion in sales in 2023.
FDA approves first RSV vaccine to protect older adults - CBS News
WEBMay 3, 2023 · Arexvy is an adjuvanted vaccine, meaning that it combines its immunogen mimicking part of the virus with an additional ingredient to trigger stronger immune responses.
AREXVY | FDA - U.S. Food and Drug Administration
WEBJun 2, 2023 · Approval History, Letters, Reviews, and Related Documents - AREXVY. For active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in ...
- Some results have been removed